Comparative study of Alendronate versus etidronate for the treatment of Paget's disease of bone

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 3, 1996, Pages 961-967

  Siris, E ^a,o   Weinstein, R S ^b   Altman, R ^c   Conte, J M ^d   Favus, M ^e   Lombardi, A ^f   Lyles, K ^g   McIlwain, H ^h   Murphy Jr , W A ⁱ   Reda, C ^f   Rude, R ^j   Seton, M ^k   Tiegs, R ^l   Thompson, D ^f   Tucci, J R ^m   Yates, A J ^f   Zimering, M ⁿ  

^a College of Physicians and Surgeons ^*  (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d Rheumatology Associates   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h Habana Medical Center   (United States)

ⁱ UNIVERSITY OF TEXAS   (United States)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l MAYO CLINIC   (United States)

^m ROGER WILLIAMS MEDICAL CENTER   (United States)

ⁿ VETERANS AFFAIRS MEDICAL CENTER   (United States)

^o New York Presbyterian Hospital Columbia University Medical Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; ETIDRONIC ACID;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE MINERALIZATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; ORAL DRUG ADMINISTRATION; PAGET BONE DISEASE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ALENDRONATE; ALKALINE PHOSPHATASE; AMINO ACIDS; BIOPSY; BONE AND BONES; CALCIUM; ETIDRONIC ACID; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEITIS DEFORMANS; PAIN; PHOSPHATES;

EID: 9044220965     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.3.961     Document Type: Article

References (24)

1. Siris ES. 1993 Paget's disease of bone. In: Favus MJ, ed. Primer on the metabolic bone disease and disorders of bone metabolism. New York: Raven Press; 375-384.
2. Bone HG, Kleerekoper M. 1992 Paget's disease of bone. J Clin Endocrinol Metab. 75:1179-1182.
3. Fleisch H. 1993 Bisphosphonates in osteoporosis: an introduction. Osteoporos Int. 3(Suppl 3):S3-S5.
4. Boyce BF, Smith L, Fogelman I, Johnston E, Ralston S, Boyle IT. 1984 Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet. 1:821-824.
5. Weinstein RS. 1982 Focal mineralization defect during disodium etidronate treatment of calcinosis. Calcif Tissue Int. 34:244-248.
6. Hosking DJ. 1990 Advances in the management of Paget's disease of bone. Drugs. 40:829-840.
7. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Porras AG. 1993 Clinical pharmacology of alendronate sodium. Osteoporos Int. 3(Suppl 3):S13-S16.
8. Rodan GA, Seedor JG, Balena R. 1993 Preclinical pharmacology of alendronate. Osteoporos Int. 3(Suppl 3):S7-S12.
9. Balena R, Toolan BC, Shea M, et al. 1993 The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest. 92:2577-2586.
10. Sato M, Grasser W, Endo N, et al. 1991 Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 88:2095-3105.
11. O'Doherty DP, Bickerstaff DR, McCloskey EV, et al. 1990 Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate. J Bone Miner Res. 5:483-491.
12. Adami S, Mian M, Gatti P, et al. 1994 Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. Bone. 15:415-417.
13. Filipponi P, Pedetti M, Beghe F, Giovagnini B, Miam M, Cristallini S. 1994 Effects of two different bisphosphonates on Paget's disease of bone. ICTP assessed. Bone. 15:261-267.
14. Cleeland CS. 1990 Assessment of pain in cancer. Adv Pain Res Ther. 16:47-55.
15. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD. 1990 Urinary excretion of pyridinium crosslinks. A new marker of bone resorption in metabolic bone disease. Bone Miner. 8:87-96.
16. Parfitt AM, Drezner MK, Glorieux FH, et al. 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res. 2:595-610.
17. Weinstein RS, Bell NB. 1988 Diminished rates of bone formation in normal black adults. N Engl J Med. 319:1698-701.
18. Gray RES, Yates AJ, Preston CJ, Smith R, Russell RGG, Kanis JA. 1987 Duration of effect of oral diphosphonate therapy in Paget's disease of bone. Q J Med. 245:755-767.
19. Anderson DC, Richardson PC. 1994 Pamidronate and Paget's disease. Lancet. 343:427.
20. McCloskey EV, Yates AJ, Beneton MNC, Galloway J, Harris S, Kanis JA. 1987 Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone. 8(Suppl 1):S35-S41.
21. Yates AJ. 1988 Paget's disease of bone. Bailliere Clin Endocrinol Metab. 2:267-285,
22. Walton RJ, Russell RGG, Smith R. 1975 Changes in the renal and extra-renal handling of phosphate induced by disodium etidronate in man. Clin Sci Mol Med. 49:45-56.
23. Bisphosphonates. 1992 Facts and comparisons. St. Louis: Lippincott; 134f-134m.
24. Kanis JA, Urwin GH, Gray RES, et al. 1987 Effects of intravenous etidronate disodium on skeletal and calcium metabolism. Am J Med. 82(Suppl 2A):55-70.